Agilent Highlights Genomics and Cell Analysis Solutions for Cancer Research at AACR 2022
08 Abril 2022 - 9:00AM
Business Wire
Agilent Technologies Inc. (NYSE: A) today announced cancer
research innovations in cell analysis and genomics that will be on
show at the American Association for Cancer Research Annual
Meeting, being held April 8 - 13, 2022 in New Orleans,
Louisiana.
“Cancer research is an important focus area for Agilent. The
AACR conference presents an exciting opportunity to engage with
customers, partners, and thought leaders in this field,” said Jodi
Barrientos, vice president of Commercial Marketing for Agilent’s
Diagnostics and Genomics Group. “We look forward to highlighting
products that enable the analysis of different sample types by
leveraging multimodal approaches to cancer research spanning cell
analysis, LCMS, and genomics.”
Agilent is committed to helping cancer researchers achieve their
scientific objectives by providing a broad toolkit of innovative
products and solutions. Furthermore, Agilent’s portfolio of
cancer-relevant solutions serves customers globally in their work
on cancer research, diagnosis, and therapeutic development.
One of the solutions on show at ACCR is the Agilent Magnis NGS
Prep System. This automated benchtop solution has an onboard wizard
that allows assays to be set up in under five minutes, enabling
molecular pathologists to profile samples for various generic
aberrations using a single, cost-effective, and efficient
platform.
Also featured will be the Agilent XF Pro Analyzer demonstrating
its advanced functionality, particularly its capability to enhance
critical aspects of monitoring live cells in real-time. The XF Pro
incorporates enhancements that improve measurement performance and
data interpretation, making it easier to identify novel drug
targets, validate target effect on cellular function, optimize
disease models, and determine drug safety and antitumor potential
of T cell therapies.
Visit Agilent at booth #1619 to learn more.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in the
life sciences, diagnostics, and applied chemical markets,
delivering insight and innovation that advance the quality of life.
Agilent’s full range of solutions includes instruments, software,
services, and expertise that provide trusted answers to our
customers' most challenging questions. The company generated
revenue of $6.32 billion in fiscal 2021 and employs 17,000 people
worldwide. Information about Agilent is available at
www.agilent.com. To receive the latest Agilent news, please
subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn,
Twitter, and Facebook.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220408005238/en/
Naomi Goumillout Agilent Technologies +1.781.266.2819
naomi.goumillout@agilent.com
Agilent Technologies (NYSE:A)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Agilent Technologies (NYSE:A)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024